Abstract:Résumé La granulomatose septique chronique (CGD) est un déficit immunitaire héréditaire qui affecte les capacités oxydatives des cellules phagocytaires et se caractérise par une susceptibilité accrue aux infections bactériennes et fongiques ainsi que par une hyper inflammation granulomateuse. Les manifestations pulmonaires, fréquentes, sont de 2 types : (1) infectieuses : souvent très sévères, découvertes à un stade tardif du fait du caractère pauci-symptomatique initial. Leur incidence a diminué grâce aux prophylaxies anti-infectieuses systématiques mais reste une cause majeure de morbi-mortalité ; (2) inflammatoires : masse granulomateuse persistante ou pneumopathie interstitielle. La récurrence des complications pulmonaires depuis l'enfance génère des séquelles parenchymateuses et bronchiques impactant le pronostic fonctionnel. L'allogreffe de cellules souches hématopoïétiques est un traitement curatif ; sa place est discutée pour préserver le pronostic vital et limiter la morbidité de la maladie. Grâce aux progrès de prise en charge, l'espérance de vie a considérablement augmenté. De nouvelles problématiques apparaissent chez les sujets adultes : difficultés d'observance, augmentation des manifestations inflammatoires, résistances acquises aux anti-infectieux. Ceci souligne l'importance de la période de transition et la nécessité d'une prise en charge multidisciplinaire. Summary Chronic Granulomatosis Disease (CGD) is an inherited immune deficiency due to a mutation in the genes coding for the subunits of the NADPH oxidase enzyme that affects the oxidative capacity of phagocytic cells. It is characterized by increased susceptibility to bacterial and fungal infections, particularly Aspergillus , as well as complications associated with hyperinflammation and granulomatous tissue infiltration. There exist two types of frequently encountered pulmonary manifestations: (1) due to their being initially pauci-symptomatic, possibly life-threatening infectious complications are often discovered at a late stage. Though their incidence has decreased through systematic anti-bacterial and anti-fungal prophylaxis, they remain a major cause of morbidity and mortality; (2) inflammatory complications consist in persistent granulomatous mass or interstitial pneumoniae, eventually requiring immunosuppressive treatment. Pulmonary complications recurring since infancy generate parenchymal and bronchial sequelae that impact functional prognosis. Hematopoietic stem cell allograft is a curative treatment; it is arguably life-sustaining and may limit the morbidity of the disease. As a result of improved pediatric management, life expectancy has increased dramatically. That said, new challenges have appeared with regard to adults: difficulties of compliance, increased inflammatory manifestations, acquired resistance to anti-infectious therapies. These different developments underscore the importance of the transition period and the need for multidisciplinary management.

Genetic Characteristics, Infectious, and Noninfectious Manifestations of 32 Patients with Chronic Granulomatous Disease

Clinical presentation, diagnosis, and treatment of chronic granulomatous disease

Inflammatory Complications in Chronic Granulomatous Disease

Phenomic Analysis of Chronic Granulomatous Disease Reveals More Severe Integumentary Infections in X-Linked Compared With Autosomal Recessive Chronic Granulomatous Disease

Preimplantation genetic testing for X-linked chronic granulomatous disease induced by a CYBB gene variant: A case report

Chronic granulomatous disease. Report on a national registry of 368 patients

Genotype-Phenotype Correlations in Chronic Granulomatous Disease: Insights From a Large National Cohort

High Levels of IL-18 and IFN-γ in Chronically Inflamed Tissue in Chronic Granulomatous Disease

A Case of Chronic Granulomatous Disease Masquerading As Tubercular Lymphadenitis in an Infant

Complications pulmonaires de la granulomatose septique chronique

Molecular quality control machinery contributes to the leukocyte NADPH oxidase deficiency in chronic granulomatous disease.

First Report on Chronic Granulomatous Disease from Nepal and a Review of CYBC1 Deficiency

Variant Type X91+ Chronic Granulomatous Disease: Clinical and Molecular Characterization in a Chinese Cohort

Diminished production of anti-inflammatory mediators during neutrophil apoptosis and macrophage phagocytosis in chronic granulomatous disease (CGD)

A homozygous loss-of-function mutation leading to CYBC1 deficiency causes chronic granulomatous disease

P102 Cutaneous noninfectious manifestations of chronic granulomatous disease: a prospective study

A Cohort of 169 Chronic Granulomatous Disease Patients Exposed to BCG Vaccination: a Retrospective Study from a Single Center in Shanghai, China (2004–2017)

S2766 A Rare Case of Chronic Granulomatous Disease in a Patient With Crohn's Disease

Clinical and Molecular Features of Chronic Granulomatous Disease in Mainland China and a XL-CGD Female Infant Patient After Prenatal Diagnosis

[Relationship Between Gh Genotyping and Clinical Characteristics of Children with Congenital Cytomegalovirus Infection].

Olfm4 deletion enhances defense against Staphylococcus aureus in chronic granulomatous disease.